IOBT IO Biotech Inc: Enterprise Value-to-Revenue Multiple

Public company logo of iobiotech.com (IOBT)

IO Biotech, Inc. (IOBT) develops advanced immunomodulating vaccines designed to transform the tumor environment and combat cancer. The company implements robotic laboratories and cloud software for genomic data analysis. The business is centered around the T-win ecosystem, featuring unique patents for T-cell activation. The EV/Sales history illustrates the business value-to-revenue trend, where the value remains around 0.00.

Company Value to Revenue: IO Biotech Inc (IOBT) for 11/23/2025 - 04/18/2026

iobiotech.com - analytical breakdowns and key metrics (IOBT)

- share price and consensus valuation forecast:
Initial company analysis:IO Biotech, Inc. IOBT
Product sample of IO Biotech, Inc.

The enterprise value-to-revenue trajectory reflects the market valuation of the biopharmaceutical potential of IO Biotech, Inc. (IOBT) in the development of cancer therapies. The EV/Sales metric compares the total value of the business with sales volume, excluding the impact of debt load. The calculation is based on the sum of market capitalization and net debt divided by annual revenue. For an innovator with the T-win platform, this indicator measures the premium for future scientific success. This analysis allows for an assessment of whether the current capitalization is fair relative to the R&D stage.

Competitor analysis for IO Biotech, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP